Rybrevant® (Amivantamab)

Rybrevant® (Amivantamab) 350 mg/7 mL Concentrate for IV Infusion: A Sourcing Guide for Hospitals and Pharmacies

Rybrevant® is an amivantamab injection (EGFR-MET bispecific antibody) marketed by Janssen, a Johnson & Johnson company. The decision to prescribe amivantamab, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.

As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Rybrevant® (amivantamab) 350 mg/7 mL concentrate for intravenous infusion to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the Cancer category. Supply is in bulk/wholesale quantities only.

---

What is Rybrevant (Amivantamab)?

Rybrevant contains amivantamab, a bispecific antibody supplied as a concentrate for intravenous infusion in a single-dose 350 mg/7 mL vial, prepared and administered by healthcare professionals. Indications and use in India are those printed in the Indian pack insert.

How it works, according to the label: The US prescribing information (DailyMed) describes amivantamab as a bispecific EGF receptor-directed and MET receptor-directed antibody.

---

Indications as Listed in the Reference Label

The current US prescribing information for Rybrevant (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Rybrevant pack insert.

• The US label lists locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, in combination with lazertinib, first-line
• The US label lists NSCLC with EGFR exon 20 insertion mutations in combination with chemotherapy
• The US label lists NSCLC with EGFR exon 20 insertion mutations after disease progression on or after platinum-based chemotherapy, as monotherapy
• Patient selection is by an FDA-approved test; refer to the current prescribing information

---

Clinical Studies and Evidence

Published studies of amivantamab include CHRYSALIS (J Clin Oncol 2021), PAPILLON (N Engl J Med 2023) and MARIPOSA (N Engl J Med 2024). Results and conclusions are those of the trial authors and the prescribing information; A.K. Pharma does not interpret them.

---

Available Strengths and Packs

Strength	Dosage form	Pack (confirm against the carton)
Amivantamab 350 mg/7 mL	Concentrate for solution for IV infusion	Single-dose vial (confirm against the carton)

Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.

---

Key Benefits for Procurement

• Genuine, sealed original-pack stock sourced through authorised channels
• Single-vial presentation of a specialty oncology biologic available from one source
• Batch and expiry details provided on request
• Cold-chain aware handling and storage of biologic stock before dispatch
• Documentation support for hospital purchase departments

---

Who Is This Page For?

Hospitals, oncology and thoracic-oncology centres, day-care infusion units and pharmacies in India that need to source Rybrevant in bulk quantities from a licensed distributor.

---

Possible Side Effects Reported in the Label

Side effects are listed in the prescribing information and Indian pack insert and are not summarised here. Refer to the label and consult the treating physician.

---

Precautions

• Use only as prescribed by a registered medical practitioner.
• Read the full prescribing information before use.
• Intravenous presentations are for preparation and administration by healthcare professionals.
• Check carton, batch number and expiry date on receipt.

All use should follow the approved prescribing information and the instructions of the treating physician.

---

Storage and Handling

Store refrigerated at 2°C to 8°C in the original carton, protected from light, as directed on the pack. Do not freeze or shake.

---

Manufacturer Information

Rybrevant is marketed by Janssen, a Johnson & Johnson company. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Rybrevant through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.

---

Related Medicines

• Opdivo
• Imfinzi
• Tagrisso
• Yervoy
• Lynpraza
• Blincyto
• Adcetris
• Venclexta
• All cancer medicines
• Patient Assistance Program

---

Frequently Asked Questions

Is Rybrevant available in India?
A.K. Pharma supplies Rybrevant® (amivantamab) 350 mg/7 mL concentrate for intravenous infusion to hospitals and pharmacies in India. Contact us for current availability.

What does Rybrevant contain?
Rybrevant contains amivantamab, marketed by Janssen (Johnson & Johnson). The details of use are those on its label.

Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.

Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.

How do I request a quote?
Call or WhatsApp us, or use the contact details below.

---

Why Order from A.K. Pharma

• Licensed pharmaceutical distributor in Delhi with 25+ years in specialty medicines
• Genuine, original-pack stock
• Bulk/wholesale supply to hospitals and pharmacies
• Batch and expiry details on request
• Dedicated team for hospital procurement queries

---

Sources and Further Reading

• DailyMed: Rybrevant (amivantamab) prescribing information
• PubMed: CHRYSALIS study
• PubMed: PAPILLON trial
• PubMed: MARIPOSA trial
• MedlinePlus: Lung cancer
• MedlinePlus: Monoclonal antibodies

---

Contact A.K. Pharma for Rybrevant Supply

📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in

---

Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.